CD123

LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results

Retrieved on: 
tisdag, maj 21, 2024
Patient, MDS, Pembrolizumab, Bone marrow, Investment, Clinical trial, AML, Prostate cancer, Research, CD123, LAVA, Myelodysplastic syndrome, Combination therapy, Acute myeloid leukemia, CRS, Pharmaceutical industry

“LAVA continues to advance our pipeline of Gammabody programs and is excited to initiate the combination arm of pembrolizumab with LAVA-1207 this quarter.

Key Points: 
  • “LAVA continues to advance our pipeline of Gammabody programs and is excited to initiate the combination arm of pembrolizumab with LAVA-1207 this quarter.
  • We look forward to sharing an update on the LAVA-1207 program during the second half of 2024,” said Stephen Hurly, President and Chief Executive Officer of LAVA.
  • Research and development expenses were $6.0 million and $9.9 million for the quarters ended March 31, 2024 and 2023, respectively.
  • General and administrative expenses were $2.9 million and $3.9 million for the quarters ended March 31, 2024 and 2023, respectively.

Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program

Retrieved on: 
torsdag, maj 16, 2024
Partnership, Molecular imaging, Delta, Novartis, HSC, IND, Bone marrow, Cytokine release syndrome, Congress, AML, CD70, EHA, Hematopoietic stem cell transplantation, Depreciation, Therapy, District court, Molecule, CD33, Conference, CD47, Society, Annual, Alpha particle, B cell, Physician, Half-life, DARPin, ASH, DRS, Stem cell, Molecular Partners, Safety, Tetra, Gene family, ASCO, FAP, Radionuclide, DLL3, CD40, CHF, European Hematology Association, Antigen, Patient, Prejudice, HSCT, SNMMI, Partner, RDT, ELN, CD123, DSM-IV codes, Pharmaceutical industry

For our emerging pipeline, we plan to announce preclinical data from our Switch-DARPin Platform at EHA and anticipate translational efficacy data in the second half of 2024.

Key Points: 
  • For our emerging pipeline, we plan to announce preclinical data from our Switch-DARPin Platform at EHA and anticipate translational efficacy data in the second half of 2024.
  • Of this figure, approximately CHF 8 million will be non-cash effective costs for share-based payments, IFRS pension accounting and depreciation.
  • With CHF 174.1 million in cash and short-term time deposits and no debt as of March 31, 2024, the Company expects to be funded well into 2026.
  • The first Switch-DARPin program (cKIT x CD16a x CD47) was introduced at the annual J.P. Morgan Healthcare Conference in January 2024.

Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress

Retrieved on: 
onsdag, maj 15, 2024
Research, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Lymphoma, Sanofi, Patient, Relapse, IPH, Safety, Congress, IPHA, EHA, Abstract, CD20, Bone marrow, CD123, Society, High, Euronext Paris, Pharmaceutical industry

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate’s drug candidates have been accepted for the European Association of Hematology (EHA) 2024 Congress, taking place June 13-16, 2024 in Madrid, Spain.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate’s drug candidates have been accepted for the European Association of Hematology (EHA) 2024 Congress, taking place June 13-16, 2024 in Madrid, Spain.
  • Two abstracts are related to SAR443579 (IPH6101), an investigational trifunctional anti-CD123 NKp46xCD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi and currently being evaluated as a monotherapy in a Sanofi-sponsored Phase 1/2 clinical trial for the treatment of blood cancers with high unmet needs.
  • Two abstracts are related to IPH6501, Innate’s second generation ANKET® for the treatment of relapsed or refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma, currently in Phase 1/2 clinical trial.
  • “We’re pleased to see a continued momentum around our ANKET® platform assets, SAR443579 and IPH6501,” said Dr. Sonia Quaratino, Chief Medical Officer of Innate Pharma.

Innate Pharma Reports First Quarter 2024 Business Update and Financial Results

Retrieved on: 
tisdag, maj 14, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, EV, Drug, Relapse, PDX, MF, FDA, Form, CD20, Carcinoma, Amyloidosis, Euronext Paris, Acute myeloid leukemia, Randomized controlled trial, B-ALL, NK, AACR, Telephone, ADC, Neoplasm, PD-1, ATM, NHL, CRT, Acute lymphoblastic leukemia, GEMOX, Food, NSCLC, EVP, ADS, IPHA, Cancer, ASCO, Poster, BCMA, Oxaliplatin, AstraZeneca, Takeda, Bone marrow, IPH, Lung cancer, Prospectus, PTCL, Spacecraft, CD123, Abstract, Webcast, Pharmaceutical industry

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the quarter ending March 31, 2024.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the quarter ending March 31, 2024.
  • Top-line results in MF patients will be presented at the ASCO Annual Meeting 2024 being held May 31 – June 4 in Chicago.
  • Cash, cash equivalents and financial assets of the Company amounted to €113.9 million as of March 31, 2024.
  • Cash, cash equivalents and financial assets as of March 31, 2024 do not include the €4.0 million payment to be received from Sanofi.

MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data

Retrieved on: 
torsdag, maj 9, 2024
SCCHN, Gilead Sciences, Safety, SN-38, Pleural effusion, Neck, Colorectal cancer, Research, HEAT, Pneumonitis, SCLC, Security (finance), Lung cancer, Webcast, Carcinoma, Docetaxel, IND, Syndrome, CD123, Cardiac arrest, ADC, Patient, ADAM, DXD, Lung, Enoblituzumab, Melanoma, Death, MDR, Head, AACR, Acute myeloid leukemia, ID, Cancer, Telephone, NSCLC, Spacecraft, Anal cancer, Vaccine

The final decision to pursue such a Phase 3 study will be based on an analysis of the final data set, including rPFS, when available.

Key Points: 
  • The final decision to pursue such a Phase 3 study will be based on an analysis of the final data set, including rPFS, when available.
  • MacroGenics continues to enroll a Phase 1/2 dose escalation study of vobra duo in combination with lorigerlimab in patients with various advanced solid tumors.
  • The Company anticipates commencing a dose expansion study of this combination in mCRPC and at least one additional indication in 2024.
  • The HEAT study, an investigator-sponsored, randomized Phase 2 clinical trial being conducted by MacroGenics’ academic collaborators, is ongoing.

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Retrieved on: 
torsdag, maj 9, 2024
CD33, Cancer, Gene expression, Cell, Cranial cavity, Myelodysplastic syndrome, DRI, EHA, Survival, Temozolomide, Research and development, Canadian Aviation Regulations, GBM, AML, Leukemia, IND, ASCO, CD123, Patient, Gene, CML, Society, Acute myeloid leukemia, AACR, Annual general meeting, MDS, Acute leukemia, Pharmaceutical industry

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results for the first quarter ended March 31, 2024 and recent corporate highlights.

Key Points: 
  • (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results for the first quarter ended March 31, 2024 and recent corporate highlights.
  • “We continued to make significant progress advancing our gamma-delta T cell programs in the first quarter of 2024,” said William Ho, CEO and co-founder of IN8bio.
  • INB-100: Report updated interim results from the ongoing Phase 1 investigator-sponsored trial at the 2024 EHA Annual Meeting, held June 13-16 in Madrid, Spain.
  • INB-200: Report interim Phase 1 long-term follow up results in GBM at multiple medical meetings in 2024 including at the 2024 ASCO Annual Meeting.

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

Retrieved on: 
tisdag, april 9, 2024
Acute leukemia, Canadian Aviation Regulations, Cell, CD33, AML, Patient, Tissue, CML, Acute myeloid leukemia, Leukemia, Death, AACR, Neoplasm, Cancer, Safety, CD123, Antigen, Vaccine

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced new preclinical data from its non-signaling gamma-delta T cell based Chimeric Antigen Receptor-T cell (nsCAR) platform, known as INB-300, that demonstrated improved selectivity to target leukemia cells while preserving healthy ones. The data support the potential for nsCAR to have a wider therapeutic window and to be used to prevent on-target off-tumor killing of healthy tissue that may express the CAR-T target. The data was presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024 on April 9, 2024.

Key Points: 
  • The data was presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024 on April 9, 2024.
  • IN8bio's nsCAR platform is based on the natural ability of gamma-delta T cells to distinguish between healthy and malignant tissue.
  • Approved CAR-T therapies have shown remarkable efficacy against B cell malignancies, offering hope to patients with limited treatment options.
  • “These results can potentially improve INB-300, as we advance towards IND enabling studies of our next-generation gamma-delta T cell therapies to treat cancers.”

LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results

Retrieved on: 
onsdag, mars 20, 2024
Research, LAVA, AML, Risk, Patient, Acute myeloid leukemia, CRS, Syndrome, Cancer, Completeness, Pembrolizumab, IND, DLT, Investment, Bone marrow, Infrared spectroscopy correlation table, Premedication, CD123, MDS, Cytokine release syndrome

LAVA 1207 – In Phase 1/2a -- Next update expected H2 2024 targeting a medical conferenceDesigned to mediate potent killing of prostate-specific membrane antigen (PSMA)-positive prostate cancer cells

Key Points: 
  • LAVA-1207 has enrolled dose level 9 in our Phase 1/2a trial of patients with metastatic castration-resistant prostate cancer (mCRPC).
  • We continue to be encouraged by the favorable safety profile and preliminary signs of anti-tumor activity.
  • We plan to provide new data for LAVA-1207 at an upcoming medical conference in the second half of 2024,” said Stephen Hurly, President and Chief Executive Officer of LAVA.
  • “These advances represent important steps for our proprietary Gammabody® T-cell engagers as we evaluate their potential to treat cancer.

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Retrieved on: 
torsdag, mars 14, 2024
CD33, GSK, Patient, Macrophage, Society, CD3, CD47, DLL3, Therapy, Molecular Partners, TME, Partner, DRS, ASH, AML, SNMMI, Partnership, RDT, Radionuclide, Tetra, Novartis, HSCT, MHS, FTE, Exposition, Delta, Safety, SITC, Amgen, Hematopoietic stem cell transplantation, FAP, Disease, Nuclear medicine, Immunotherapy, District court, Neoplasm, EANM, Alpha particle, JNJ, Tumor microenvironment, Gene family, CD70, AACR, CD40, CHF, CD123, NK, Engineering, Antigen, Molecule, Annual general meeting, Toxicity, CD16, B cell, Conference, MBA, DARPin, Data, Molecular imaging, Pharmaceutical industry

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.
  • “2023 was a year of successful innovation and execution on our strategy, focusing on novel mechanisms that we believe only DARPin therapies can deliver.
  • In addition to the above updates, Molecular Partners continued to progress its RDT portfolio of projects in partnership with Novartis.
  • In the financial year 2023, Molecular Partners recognized total revenues and other income of CHF 7.0 million (2022: CHF 189.6 million) and incurred total expenses of CHF 68.1 million (2022: CHF 73.0 million).

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
torsdag, mars 14, 2024
MGMT, Research, Survival, ASH, CD33, Environment, Patient, GBM, Neoplasm, Temozolomide, D&O, IND, AACR, Glioblastoma, Exposition, Research and development, Society, CD123, PFS, Cell, DRI, Cranial cavity, Pharmaceutical industry

(Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023.

Key Points: 
  • (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023.
  • “IN8bio entered 2024 with significant momentum behind the company,” said William Ho, CEO and co-founder of IN8bio.
  • “Despite the difficult environment in 2023, the IN8bio team executed operationally and successfully advanced our programs.
  • Cash position: As of December 31, 2023, the Company had cash of $21.3 million, compared to $18.2 million as of December 31, 2022.